Tenascin-C in human cardiac pathology

Clinica Chimica Acta

Volumn 413, Issue 19-20, 2012, Pages 1516-1518

  Niebroj Dobosz, Irena ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Cardiac biomarkers; Cardiomyopathy; Tenascin C

Indexed keywords

BIOLOGICAL MARKER; MATRIX METALLOPROTEINASE; OSTEOPONTIN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TENASCIN; TROPONIN T;

ACUTE HEART INFARCTION; CELL ADHESION; CELL INFILTRATION; CONGESTIVE CARDIOMYOPATHY; DISEASE ASSOCIATION; DISEASE MARKER; HEART DISEASE; HEART FUNCTION; HEART INJURY; HEART MUSCLE CELL; HUMAN; MOLECULAR PATHOLOGY; MYOCARDITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REVIEW; TISSUE REPAIR; UPREGULATION;

ACUTE DISEASE; BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; FIBRONECTINS; GENE EXPRESSION; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIUM; PROGNOSIS; TENASCIN; WOUND HEALING;

EID: 84863490711     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.06.011     Document Type: Review

References (38)

1. Imanaka-Yosida K., Hiroe M., Yoshida T. Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. Histol Hisopathol 2004, 19:517-525.
2. Tucker R.P., Chiquet-Ehrisman R. The regulation of tenascin expression by tissue microenvironments. Biochim Biophys Acta 2009, 193:888-892.
3. Mackie E.J., Halfter W., Liverani D. Induction of tenascin in healing wounds. J Cell Biol 1988, 107:2757-2767.
4. Imanaka-Yoshida K., Matsumoto K., Hara M., Sakakura T., Yoshida T. The dynamic expression of tenascin-C and tenascin X during early heart development. Differentiation 2003, 71:291-298.
5. Chiquet-Ehrishmann R., Tucker R.P. Connective tissues: signaling by tenascins. Int J Biochem Cell Biol 2004, 36:1085-1089.
6. Orend G., Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett 2006, 244:143-146.
7. Tamura A., Kusachi S., Nogami K., Yamanishi A., Kajikawa Y., Hirohata S., et al. Tenascin expression in cardiomyocardial biopsy specimens in patients with dilated cardiomyopathy: distribution along margines of fibrotic lesions. Heart 1996, 75:291-294.
8. Aso N., Tamura A., Nasu M. Cirulating tenascin-C in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2004, 94:1468-1470.
9. Imanaka-Yoshida K., Hiroe M., Nishikawa T., Ishiyama A., Shimojo T., Ohta Y., et al. Tenascin -C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest 2001, 81:1015-1024.
10. Sato S., Aonuma K., Imanaka-Yoshida K., Yoshida T., Isobe M., Kawase D., et al. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol 2006, 47:2319-2325.
11. Imanaka-Yosida K., Hiroe M., Yasutomi Y., Toyazaki T., Tsuchiya T., et al. Tenascin is a useful marker for disease severity in myocarditis. J Pathol 2002, 197:388-394.
12. Morimoto S., Imanaka-Yoshida, Hiramitsu S., Kato S., Ohtski M., Uemura A., et al. Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. J Pathol 2005, 205:460-467.
13. Frangogiannis N.G., Shimoni S., Chang S., Ren G., Dewald O., Gersch C., et al. Active interstitial remodeling: an important process in the hibernating human myocardium. J Am Coll Cardiol 2002, 39:1468-1474.
14. Midwood K.S., Hussenet T., Langlois B., Orens G. Advances in tenascin-C biology. Cell Mol Life Sci 2011, 68:3175-3199.
15. Fujimoto N., Onishi K., Sato A., Teraski F., Tsukada B., Nozato T., et al. Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure. J Card Fail 2009, 15:898-905.
16. Terasaki F., Okamoto H., Onishi K., Sato A., Shimomura H., Tsukada B., et al. Higher serum tenascin C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J 2007, 71:327-330.
17. Tsukada B., Terasaki F., Shimomura H., Otsuka K., Otsuka K., Katashima T., et al. High prevalence of chronic myocarditis in dilated cardiomyopathy referred for left ventriculopasty: expression of tenascin-Cas a possible marker for inflammation. Hum Pathol 2009, 40:1015-1022.
18. Niebroj-Dobosz I., Madej-Pilarczyk A., Marchel M., Sokolowska B., Hausmanowa-Petrusewicz I. Circulating tenascin-C levels in patients with dilated cardiomyopathy in the course of Emery-Dreifuss muscular dystrophy. Clin Chim Acta 2011, 412:1533-1538.
19. Niebroj-Dobosz I., Madej-Pilarczyk A., Marchel M., Sokolowska B., Hausmanowa-Petrusewicz I. Osteopontin - a fibrosis-related marker- in dilated cardiomyopathy in patients with Emery-Dreifuss muscular dystrophy. Scand J Clin Lab Invest 2011, 71:658-662.
20. Brodsky G.L., Muntoni F., Miocic S., Sinagra G., Sewry C., Mestroni L. Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation 2000, 101:473-476.
21. De Siqueira Carvahlo A.A., Levy J.A., Gutierrez P.S., Nagahashi K., Narie S., Sosa E.A., et al. Emery-Dreifuss muscular dystrophy. Arq Neuropsiquiatr 2000, 58:1123-1127.
22. Kim S.E., Hong J.S., Ahn J.S., Kim J.S., Kim D.K. A case of Emery-Dreifuss musculardystrophy by emerin mutation. Korean Circ J 2003, 33:143-149.
23. Merchut M., Zdonczyk D., Gujrati M. Cardiac transplantation in female Emery-Dreifuss muscular dystrophy. J Neurol 1990, 237:316-319.
24. Hessel M.H., Bleeker G.B., Bax J.J., Henneman M.M., del Adel B., Klok M., et al. Reverse ventricular remodeling after cardiac resynchronozation therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. Eur J Heart Fail 2007, 9:1058-1063.
25. Missov E., Calzolari C., Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997, 96:2953-2958.
26. Setsuta K., Seino Y., Takahashi N., Ogawa T., Sasaki K., Karada A., et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol 1999, 84:608-611.
27. Klappacher G., Franzen P., Haab D., Mehrabi M., Binder M., Plesch K., et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 1995, 75:913-919.
28. Hørslev-Petersen K., Pedersen L.R., Bentsen K.D., Brocks D., Garbarschl C., Kim K.Y., et al. Collagen type IV and procollagen type III during granulation tissue formation: a serological biochemical, immunohistochemical and morphometrical study on the viscose cellulose sponge rat model. Eur J Clin Invest 1988, 18:352-359.
29. Hørslev-Petersen K., Kim K.Y., Pedersen L.R., Bentysen K.D., Uldbjerg M., Oxfund H., et al. Serum aminoterminal type III procollagen peptide: Serum aminoterminal type III procollagen peptide: relation to biosynthesis of collagen III in experimentally induced granulation tissue in rats. Acta Pathol Microbiol Immunol Scand 1998, 96:793-804.
30. Poulsen S.H., Høst N.B., Jensen S.B., Egstrup K. Relationship between serum aminoterminal propeptide of type III procollagen and changes of left ventricel function after acute myocardial infarction. Circulation 2000, 101:1527-1532.
31. Willems I.E., Arends J.W., Daemen M.J. Tenascin and fibronectin expression in healing human myocardial scars. J Pathol 1996, 179:321-325.
32. Jian B., Jones P.L., Li Q., Mohler E.R., Schoen F.J., et al. Matrix-metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 2001, 159:321-327.
33. Murakami R., Yamaoka I., Sakakura T. Appearance of tenascin in healing skin of the mouse: possible involvement in seaming of wounded tissue. Int J Dev Biol 1989, 33:439-444.
34. Okada A. Expression of tenascin in human gastric mucosa. Mie Med J 1990, 40:251-257.
35. Udalova A., Ruhmann M., Thompson S.J., Midwood K.S. Expression and immune function of tenascin-C. Crit Rev Immunol 2011, 31:115-145.
36. 111In monoclonal antibody specific for tenascin-C. Circulation 2002, 106:1397-1402.
37. Milting H., Ellinghaus P., Seewald M., Cakar H., Bohms B., Kassner A., et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulator support devices. J Heart Lung Transplant 2008, 27:589-596.
38. Dobaczewski M., Gonzales-Quesada C., Frangogiannis N.G. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol 2010, 48:504-511.